While clinical data for AMT-130 remains strong, the FDA's insistence on a costly and time-consuming Phase III trial introduces significant development risk and timeline uncertainty. The strengthened balance sheet supports long-term funding, but investors should monitor the design and feasibility of the future trial, as well as safety developments in AMT-191 and AMT-162.
QURE drugs
QURE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $10.50entry
- T+1 · 9mo ago −14.00%α −13.09% · $9.03
- T+5 · 8mo ago +71.33%α +72.54% · $17.99
- T+20 · 8mo ago +40.29%α +48.22% · $14.73
- T+60 · 6mo ago +139.52%α +130.20% · $25.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
uniQure reported financial results for 2025, showing a revenue decline to $16.1 million and a reduced net loss of $199.0 million, or $3.46 per share, compared to $239.6 million in 2024. The company highlighted clinical progress in its gene therapy pipeline, particularly durable data for AMT-130 in Huntington’s disease, but disclosed that the FDA rejected the use of external controls for approval and mandated a randomized Phase III trial. With $622.5 million in cash, uniQure is funded into 2029.
Key Financial Metrics
Key Facts
- Revenue decreased to $16.1 million in 2025 from $27.1 million in 2024, driven by lower collaboration and contract manufacturing revenue.
- Net loss narrowed to $199.0 million ($3.46/share) from $239.6 million ($4.92/share) in 2024.
- FDA rejected approval pathway for AMT-130 based on single-arm trial with external controls; required a randomized, sham-controlled Phase III study.
- AMT-130 showed statistically significant 75% slowing in disease progression at 36 months in high-dose patients.
- Cash, cash equivalents, and investments totaled $622.5 million as of December 31, 2025, up from $367.5 million in 2024.
- Cash runway now extends into the second half of 2029, supported by $404.2 million raised in public offerings in 2025.
- Development of AMT-191 paused due to dose-limiting liver toxicities; AMT-162 enrollment remains on hold after a serious adverse event.
Financial Impact
Revenue down $11 million YoY; net loss reduced by $40.6 million; cash increased by $255 million primarily from equity financing.
Risk Factors
- FDA requirement for a sham-surgery controlled trial for AMT-130 increases development cost, timeline, and ethical/enrollment challenges.
- Clinical holds and safety concerns in AMT-191 and AMT-162 could delay or derail other pipeline programs.
- Dilution risk from prior share issuances (11.8M shares + 0.5M pre-funded warrants) may weigh on shareholder sentiment despite improved cash position.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247245 |
Track record
38 reports on QURE
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers